Columbia Wanger Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Columbia Wanger Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$42.3M	Sell	495,734 -41,141	-8%	-$3.57M	0.63%	59
2017 Q3	$45.6M	Buy	536,875 +70,343	+15%	+$5.57M	0.67%	54
2017 Q2	$35.3M	Buy	466,532 +315,159	+208%	+$22M	0.5%	95
2017 Q1	$9.99M	Buy	151,373 +9,352	+7%	+$615K	0.14%	176
2016 Q4	$9M	Sell	142,021 -56,100	-28%	-$3.54M	0.13%	178
2016 Q3	$12.6M	Sell	198,121 -126,232	-39%	-$9.27M	0.17%	170
2016 Q2	$24.1M	Buy	324,353 +71,024	+28%	+$5.27M	0.28%	138
2016 Q1	$16.9M	Buy	+253,329	New	+$15.4M	0.18%	147

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Columbia Wanger Asset Management's LGND Position: Q4 2017 in Review

Columbia Wanger Asset Management reduced its Ligand Pharmaceuticals (LGND) stake by 7.7% in Q4 2017, selling an estimated $3.57M and leaving 495,734 shares worth $42.3M. The position accounts for 0.63% of the portfolio, ranked #59.

Columbia Wanger Asset Management first reported a position in LGND in Q1 2016 and has held it in 8 quarters since. The position peaked at $45.6M in Q3 2017. 298 funds tracked by Wall St. Rank hold LGND as of Q4 2017.

Columbia Wanger Asset Management held 495,734 shares of Ligand Pharmaceuticals worth $42.3M as of Q4 2017.
Columbia Wanger Asset Management sold 41,141 Ligand Pharmaceuticals shares in Q4 2017, an estimated $3.57M.
Ligand Pharmaceuticals made up 0.63% of Columbia Wanger Asset Management's portfolio in Q4 2017, its #59 holding.
Columbia Wanger Asset Management first reported a position in Ligand Pharmaceuticals in Q1 2016 and has held it in 8 quarters since.
Columbia Wanger Asset Management's Ligand Pharmaceuticals position peaked at $45.6M in Q3 2017.
298 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2017.

Based on Columbia Wanger Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.